Register here:

Missed learning about Advancing molecules from discovery to the clinic? Please fill out the registration form to watch the full episode of our on-demand fireside chat on Advancing molecules from discovery to the clinic: A blueprint.


Key discussion points:
  • How does a small biopharma company with less than 50 employees move multiple candidates from discovery to clinic and build a deep pipeline?
     
  • How can CROs with integrated capabilities be strategically used in the journey to clinic?
     
  • Key challenges in developing drugs for rare/orphan diseases
     
  • Sneak-peek into the drug discovery and development journey of Odevixibat for progressive familial intrahepatic cholestasis (PFIC)
     
  • The future of bile acid modulators as a treatment option for cholestatic liver diseases

© Syngene International Ltd.
Syngene International Ltd. Biocon Park, SEZ, Bommasandra Industrial Area - Phase - IV, Bangalore 560099 India

Moderator: Ashu Tandon | Chief Commercial Officer, Syngene International Ltd.

Ashu has 20 years of experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting, and outsourcing services in Research & Development. He has a successful track record of building multi-million dollar deals across multiple industry verticals and geographies.

As a member of Syngene's Executive Committee, he plays an important role in driving strategy related to Commercial activities. Prior to joining Syngene, Ashu was with IQVIA (formerly QuintilesIMS), Infosys and Accenture.

Panelist: Per-Göran Gillberg, Ph.D. | Vice President - Development Albireo Pharma, Inc. and Albireo AB. 

Per-Göran is one of the co-founders of Albireo AB and brings to the table more than 30 years of experience in the pharmaceutical industry. He has experience of CMC work (about 10 years) and extensive experience in pharmacology/physiology (Gastrointestinal/hepatology) and neuropharmacology from Kabi, Kabi-Pharmacia, Pharmacia-Upjohn and Pharmacia, AstraZeneca and Albireo.

Per-Göran is one of the co-founders of Albireo AB and current VP Development for Albireo Pharma Inc and its subsidiary Albireo AB. He is also affiliated to the Division of Translational Alzheimer’s Neurobiology, Karolinska Institute, Stockholm, Sweden. He is a board member of Alzinova AB, Sweden, developing vaccines for Alzheimer’s disease.

Panelist: Erik Lindström, Ph.D. | Senior Director - Translational Science, Albireo Pharma, Inc.

Erik Lindström has 20 years of experience in the pharmaceutical industry, both from Big Pharma as well as small/mid-sized pharma. He has extensive experience in the fields of non-clinical pharmacology and translational aspects to humans. 

He has been involved in Gastrointestinal and Hepatology at AstraZeneca and Albireo. At Medivir, he  was involved in the pharmacology of target-related approaches/platforms such as protease inhibitors. He has also worked on peptide therapeutics at Zealand Pharma. He has also contributed extensively to moving several small molecule programs into early clinical development. 

Panelist: Santosh S Kulkarni, Ph.D. | Associate Research Director - Discovery Chemistry, Syngene International Ltd.

Santosh has over 15 years of experience in medicinal chemistry and drug discovery. He has extensive experience in small molecule discovery programs from hit to Lead, Lead optimization and candidate selection. He also has considerable expertise in transitioning projects to development, early process R&D, enzymatic resolutions and upscaling. He has successfully led teams to deliver pre-clinical candidates, which have transitioned into clinical development.